Innovative therapeutics

Investors

Analyst Coverage

BioMarin Pharmaceutical Inc. is covered by the following analysts.

Firm Analyst
Bank of America Merrill Lynch Ying Huang
Barclays Geoff Meacham
BMO Capital Markets M. Ian Somaiya
Cowen & Company Philip Nadeau
Credit Suisse Kennen MacKay 
Deustche Bank Andrew Peters
Goldman Sachs Salveen Richter
ISI Evercore Mark Schoenebaum
Jefferies Eun Yang
JP Morgan Cory Kasimov
Leerink Swann Joseph P. Schwartz
Morgan Stanley Matthew Harrison
Morningstar Karen Andersen
Piper Jaffray Joshua Schimmer
Raymond James Chris Raymond
RBC Capital Markets Michael Yee
Robert W. Baird Michael Ulz
Stifel Nicolaus Stephen Willey
SunTrust Edward Nash
Wedbush Morgan Liana Moussatos
William Blair & Company Tim Lugo

 

Please note that any opinions, estimates or forecasts regarding BioMarin Pharmaceutical Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of BioMarin Pharmaceutical Inc. or its management. BioMarin Pharmaceutical Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.


BioMarin

Diseases

Lysosomal Storage Disorders (MPS I, MPS IVA, MPS VI) PKU, LEMS

Products

Vimizim®
Kuvan®
Naglazyme®
Aldurazyme®
Firdapse®

Patient/Physician Support Contact Information

BioMarin RareConnections
Tel: 866.906.6100
Fax: 888.863.3361
E-mail: support@biomarin-rareconnections.com

Global Medical Information

Contact Global Medical Information